Loading stock data…
$663.04+0.80 (+0.12%)
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $663.04 with a market capitalization of $232.5B. Wall Street consensus targets $683.84 (25 analysts), implying a +3.1% move over the next 12 months. The stock is currently near its 52-week high of $694.33, remaining 21.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.99B↑ | $11.01B↓ | $12.21B↑ | $11.12B↑ | $10.85B |
| Gross Profit | $4.88B↑ | $4.43B↓ | $5.01B↑ | $4.58B↑ | $4.41B |
| Operating Income | $2.19B↑ | $1.91B↓ | $2.30B↑ | $2.08B↑ | $1.92B |
| Net Income | $1.74B↑ | $1.65B↓ | $1.96B↑ | $1.62B | $1.62B |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Inst...
Academic risk and quality models computed from TMO's own filings and price history, not from analyst opinion.
Mixed: 5 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
GARCH(1,1) 30-day annualised forecast, above the current 26.6% reading.
Fama-French 5-factor market beta. The five factors explain 15% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.